Search results for "Icon"

showing 10 items of 3539 documents

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem‐cell transplantation

2011

Antifungal prophylaxis for allogeneic haematopoietic stem-cell transplant (alloHCT) recipients should prevent invasive mould and yeast infections (IFIs) and be well tolerated. This prospective, randomized, open-label, multicentre study compared the efficacy and safety of voriconazole (234 patients) versus itraconazole (255 patients) in alloHCT recipients. The primary composite endpoint, success of prophylaxis, incorporated ability to tolerate study drug for ≥100 d (with ≤14 d interruption) with survival to day 180 without proven/probable IFI. Success of prophylaxis was significantly higher with voriconazole than itraconazole (48·7% vs. 33·2%, P 10%) treatment-related adverse events were vom…

AdultMalemedicine.medical_specialtyAntifungal AgentsAdolescentItraconazoleazolesstem-cell transplantPharmacologyBiologyAspergillosisGastroenterologyYoung AdultInternal medicineAmphotericin BmedicineHumansTransplantation Homologousyeast infectionsProspective StudiesChildAdverse effectAgedVoriconazoleHaematological MalignancyHematopoietic Stem Cell TransplantationHematologyMiddle AgedTriazolesmedicine.diseaseinvasive fungal diseaseTransplantationPyrimidinesMycosesmould infectionsFemaleVoriconazoleLiver functionItraconazoleFluconazolemedicine.drugBritish Journal of Haematology
researchProduct

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

2007

Summary Background Invasive candidosis is increasingly prevalent in seriously ill patients. Our aim was to compare micafungin with liposomal amphotericin B for the treatment of adult patients with candidaemia or invasive candidosis. Methods We did a double-blind, randomised, multinational non-inferiority study to compare micafungin (100 mg/day) with liposomal amphotericin B (3 mg/kg per day) as first-line treatment of candidaemia and invasive candidosis. The primary endpoint was treatment success, defined as both a clinical and a mycological response at the end of treatment. Primary analyses were done on a per-protocol basis. This trial is registered with ClinicalTrials.gov, number NCT00106…

AdultMalemedicine.medical_specialtyAntifungal AgentsAdolescentLipoproteinsAmphotericin B/ therapeutic useMicrobial Sensitivity TestsLipoproteins/ therapeutic usePeptides CyclicEchinocandinsLipopeptideschemistry.chemical_compoundDouble-Blind MethodAmphotericin BInternal medicineAmphotericin BPeptides Cyclic/ therapeutic usemedicineHumansAdverse effectMycosisFungemiaCandidiasis/complications/ drug therapy/microbiologyAPACHEAgedddc:616Aged 80 and overVoriconazolebusiness.industryAntifungal Agents/ therapeutic useCandidiasisMicafunginGeneral MedicineMiddle Agedbacterial infections and mycosesmedicine.diseaseApacheSurgeryTreatment OutcomechemistryMicafunginFemaleCaspofunginbusinessFluconazolemedicine.drugThe Lancet
researchProduct

Topical Voriconazole as Supplemental Treatment for Acanthamoeba Keratitis

2020

Purpose Voriconazole was shown to inhibit ergosterol synthesis in various acanthamoeba species. The purpose of this study was to evaluate the clinical outcome of treatment with supplemental topical voriconazole in patients with acanthamoeba keratitis (AK). Methods All patients who had been treated for AK with voriconazole 1% drops in conjunction with topical first-line antiacanthamoeba therapy composed of polyhexamethylene biguanide (PHMB) 0.02% and propamidine isethionate 0.1% (Brolene) between November 2014 and August 2017 at the Department of Ophthalmology, University Medical Center Mainz, were included. The main outcomes were treatment failure and recurrence rate. Secondary outcomes wer…

AdultMalemedicine.medical_specialtyAntifungal AgentsVisual acuitymedicine.drug_classAntiprotozoal AgentsVisual AcuityAcanthamoebaCorneaYoung Adult03 medical and health sciences0302 clinical medicinePharmacotherapymedicineAnimalsHumansIn patientEye Infections ParasiticAgedRetrospective StudiesAged 80 and overVoriconazoleDose-Response Relationship Drugbusiness.industryBiguanideRetrospective cohort studyMiddle AgedEye infectionmedicine.diseaseDermatologyBenzamidinesOphthalmologyAcanthamoeba KeratitisAcanthamoeba keratitis030221 ophthalmology & optometryDrug Therapy CombinationFemaleVoriconazoleOphthalmic Solutionsmedicine.symptombusiness030217 neurology & neurosurgeryFollow-Up Studiesmedicine.drugCornea
researchProduct

Use of gabapentin to reduce chronic neuropathic pain in Fabry disease.

2003

The effect of the anticonvulsant gabapentin on neuropathic pain was studied in six male patients with Fabry disease, aged 15-45 years. After 4 weeks of treatment, pain, as measured using the Brief Pain Inventory, was decreased compared with baseline. Treatment was generally well tolerated. This study indicates that gabapentin should be considered as a treatment option for the neuropathic pain of Fabry disease.

AdultMalemedicine.medical_specialtyDiabetic neuropathyGabapentinAdolescentCyclohexanecarboxylic Acidsmedicine.medical_treatmentAcetatesGeneticsmedicineHumansBrief Pain InventoryAminesGenetics (clinical)gamma-Aminobutyric AcidPain Measurementbusiness.industryVascular diseaseEnzyme replacement therapymedicine.diseaseFabry diseaseSurgeryAnticonvulsantTreatment OutcomeAnesthesiaNeuropathic painFabry DiseaseNeuralgiaAnticonvulsantsGabapentinbusinessmedicine.drugJournal of inherited metabolic disease
researchProduct

Non-fatal and fatal liver failure associated with valproic acid.

2012

Little is known about hepatotoxicity associated with valproic acid (VPA), a widely used substance in neuropsychiatry.All reported cases to the German Federal Institute for Drugs and Medical Devices between 1993 and 2009 of VPA-induced serious hepatic side effects were evaluated.A total of 132 cases of serious VPA-associated liver failure were identified. Approximately one third (34.8%) occurred under VPA monotherapy, while the majority was seen with VPA plus co-medication, most frequently antiepileptics (34.8%) and benzodiazepines (16.7%). A subgroup of 34 cases (25.8%) had a fatal outcome, the largest number reported to date. Of these, 32.4% were under VPA monotherapy and 67.6% under VPA p…

AdultMalemedicine.medical_specialtyFatal outcomeAdolescentGastroenterologyBenzodiazepinesPharmacovigilancePharmacotherapyInternal medicineGermanyPharmacovigilancemedicineHumansPharmacology (medical)ChildAgedAged 80 and overValproic Acidbusiness.industryValproic AcidLiver failureInfantGeneral MedicineMiddle AgedPsychiatry and Mental healthAnesthesiaConcomitantChild Preschoollipids (amino acids peptides and proteins)AnticonvulsantsDrug Therapy CombinationFemaleChemical and Drug Induced Liver Injurybusinessmedicine.drugPharmacopsychiatry
researchProduct

Oxidative stress markers in the neocortex of drug-resistant epilepsy patients submitted to epilepsy surgery

2013

Summary Purpose While there is solid experimental evidence of brain oxidative stress in animal models of epilepsy, it has not been thoroughly verified in epileptic human brain. Our purpose was to determine and to compare oxidative stress markers in the neocortex of epileptic and non-epileptic humans, with the final objective of confirming oxidative stress phenomena in human epileptic brain. Methods Neocortical samples from drug-resistant epilepsy patients submitted to epilepsy surgery ( n =20) and from control, non-epileptic cortex samples ( n =11) obtained from brain bank donors without neurological disease, were studied for oxidative stress markers: levels of reactive oxygen species (ROS)…

AdultMalemedicine.medical_specialtyGlutathione reductaseNeocortexBiologymedicine.disease_causeLipid peroxidationSuperoxide dismutasechemistry.chemical_compoundEpilepsyInternal medicinemedicineHumansTreatment Failurechemistry.chemical_classificationGlutathione PeroxidaseReactive oxygen speciesEpilepsySuperoxide DismutaseGlutathione peroxidaseMiddle AgedCatalasemedicine.diseasePsychosurgeryOxidative StressGlutathione ReductaseEndocrinologyNeurologyBiochemistrychemistryCatalaseRetreatmentbiology.proteinAnticonvulsantsFemaleNeurology (clinical)BiomarkersOxidative stressEpilepsy Research
researchProduct

The Effectiveness of Laser-Assisted Surgical Excision of Leukoplakias and Hyperkeratosis of Oral Mucosa: A Case Series in A Group of Patients

2019

Introduction: In the different branches of dentistry, the use of laser to solve different clinical situations is increasing due to numerous advantages that have been studied in literature since the 70s. Leucoplakia and hyperkeratosis can benefit from laser-assisted treatment. In most cases biopsy sampling, histological examination and, if no malignant cells are present, the follow-up is needed. However, even if the lesion is free of dysplasia patients often ask to eliminate these white spots that are always a cause of concern. Aim: From these numerous requests comes the idea of setting up a laser-assisted protocol as less invasive as possible to be offered to patients. The aim of the study …

AdultMalemedicine.medical_specialtyHealth Toxicology and MutagenesisleucoplakiaHyperkeratosisCirurgia dentallcsh:Medicineoral medicinehyperkeratosis; laser; leucoplakia; oral medicine; oral surgeryArticleNOLesion03 medical and health sciences0302 clinical medicineBiopsymedicineHumansSampling (medicine)Oral mucosaHyperplasiahyperkeratosismedicine.diagnostic_testbusiness.industryMedical recordlcsh:RMouth MucosaPublic Health Environmental and Occupational HealthhyperkeratosiMED/28 - MALATTIE ODONTOSTOMATOLOGICHE030206 dentistryMiddle Agedmedicine.diseaseSurgerylasermedicine.anatomical_structureDysplasiaMED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICAFemaleLasers Semiconductormedicine.symptombusinessOral medicineLeukoplakia030215 immunologyoral surgery
researchProduct

Drug-induced pertubation of the aminothiol redox-status in patients with epilepsy: improvement by B-vitamins.

2008

Summary Objectives Patients with epilepsy have excess morbidity and mortality due to ischemic cardiovascular disease. Many of these patients have elevated concentrations of plasma total homocysteine (Hcy), which is an acknowledged risk factor for cardiovascular disease, venous thromboembolic disease, foetal malformations and dementia. Hyperhomocysteinemia may have negative effects through mechanisms involving oxidative damage. In the present study, we have investigated the aminothiol redox-status in patients on antiepileptic drugs. Thereafter, in a subset of patients with elevated total Hcy, we evaluated the effect of B-vitamin therapy. Methods In the first part of the study, 101 patients o…

AdultMalemedicine.medical_specialtyHyperhomocysteinemiaHomocysteinemedicine.medical_treatmentRiboflavinHyperhomocysteinemiaRiboflavinchemistry.chemical_compoundFolic AcidMethionineVitamin B DeficiencyInternal medicinemedicineHumansCysteineMethionineEpilepsybusiness.industryValproic AcidCase-control studyPyridoxineDipeptidesmedicine.diseasePyridoxineSurgeryB vitaminsEndocrinologyAnticonvulsantCarbamazepineNeurologychemistryLiverCase-Control StudiesPhenobarbitalPhenytoinDrug EvaluationAnticonvulsantsFemaleNeurology (clinical)businessOxidation-ReductionPrimidonemedicine.drugEpilepsy research
researchProduct

Side-effects of extracorporeal shock wave therapy (ESWT) in the treatment of tennis elbow

2002

Apart from a few observational reports, there are no studies on the side-effects of extracorporeal shock wave therapy (ESWT) in the treatment of insertion tendopathies. Within the framework of a randomised, placebo-controlled, single-blind, multicentre study to test the effectiveness of ESWT in the case of lateral epicondylitis (LE), side-effects were systematically recorded. A total of 272 patients from 15 centres was allocated at random to active ESWT (3 x 2000 pulses, energy flux density ED(+) 0.04 to 0.22 mJ/mm(2) under local anaesthesia) or placebo ESWT. In all, 399 ESWT and 402 placebo treatments were analysed. More side-effects were documented in the ESWT group (OR = 4.3, CI = [2.9; …

AdultMalemedicine.medical_specialtyMigraine Disordersmedicine.medical_treatmentLithotripsyPlacebolaw.inventionRandomized controlled triallawLithotripsySyncope VasovagalmedicineTennis elbowHumansSingle-Blind MethodOrthopedics and Sports Medicinebusiness.industryEpicondylitisTennis ElbowGeneral MedicineMiddle Agedmedicine.diseaseSurgerymedicine.anatomical_structureMigraineOrthopedic surgeryUpper limbFemaleSurgerybusinessArchives of Orthopaedic and Trauma Surgery
researchProduct

A comparative study of naproxen gel and flufenamic acid gel in the treatment of soft tissue injuries.

1990

One hundred patients were enrolled in a single-blind, randomized, parallel group study to compare naproxen gel (10%) with flufenamic acid gel (3%) for the treatment of soft tissue injuries. Demographic variables, the distribution of diagnoses (tendinitis, bursitis/synovitis, synovitis, periarthritis, epicondylitis) and initial severity of the complaint were similar between the two groups. The gels were applied 2 to 6 times per day, as required, and conventional clinical indices were evaluated at Day 1 (on entry to the study), Day 3 and Day 7. Global assessments of efficacy were made by both physicians and patients at the end of the study. By Day 7 both treatments had produced a highly signi…

AdultMalemedicine.medical_specialtyNaproxenBursitisAdolescentlaw.inventionNaproxenRandomized controlled trialTendinitislawBursitisSynovitismedicineHumansSingle-Blind MethodChildAgedSynovitisbusiness.industryEpicondylitisSoft tissueGeneral MedicineMiddle Agedmedicine.diseaseSurgeryFlufenamic AcidFlufenamic acidAnesthesiaTendinopathySprains and StrainsFemalebusinessGelsmedicine.drugCurrent medical research and opinion
researchProduct